Division of Developmental Biology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, UK
*Author for correspondence (e-mail: dstempl{at}nimr.mrc.ac.uk)
Accepted 29 April 2002
![]() |
SUMMARY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: Dystroglycan, Muscular dystrophy, Dystrophin, Zebrafish, Danio rerio, Sarcomere, Sarcoplasmic reticulum
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Dystroglycan is required early in mammalian embryogenesis. Mice null for dystroglycan die around the time of implantation and fail to form the basement membrane (BM) known as Reicherts membrane (Williamson et al., 1997). A major component of the BM is laminin, which polymerises to form a scaffold. Mice that lack the laminin
1 chain also fail to form Reicherts membrane and die around the time of implantation (Smyth et al., 1999
). Not all BM formation, however, is dependent on dystroglycan. Chimaeric mice generated with dystroglycan-null ES cells display a dystrophic muscle phenotype but form a normal muscle BM (Cote et al., 1999
). This suggests that dystroglycan is not essential for muscle cell BM assembly. Differences between early and late requirements for dystroglycan in BM formation may be explained by the action of other laminin receptors present in skeletal muscle.
Integrin dimers containing ß1-integrin can act as laminin receptors. ES cells lacking ß1-integrin can be made to differentiate in vitro into a variety of fates, including skeletal muscle. While ß1-integrin mutant myotubes become surrounded by laminin, electron microscopy reveals that the basement membrane is thin or absent (Lohikangas et al., 2001). Taken together, these data suggest that different laminin receptors are instrumental in BM formation in distinct tissues and at different times during embryogenesis.
Dystroglycan is also thought to be important in both the peripheral and central nervous system (CNS). The only identified binding partners for dystroglycan in the CNS are the neurexins, cell-surface proteins implicated in cell adhesion. This association suggests that dystroglycan may be involved in cell adhesion in the CNS (Sugita et al., 2001). Several studies have also implicated dystroglycan in the clustering of nicotinic acetylcholine receptors (AChR) in muscle cells, an essential feature of neuromuscular junctions (NMJ) (Chamberlain, 1999
).
To investigate the action of dystroglycan in BM assembly and assess its importance in muscle integrity and innervation, we cloned zebrafish dystroglycan cDNA, ascertained its expression pattern during embryogenesis and removed its function using antisense morpholino oligonucleotides (MO).
![]() |
MATERIALS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We predicted the start of translation to be a leucine because the DNA sequence indicates the presence of a consensus Kozak sequence and the first 22 residues of a signal peptide (Nielsen et al., 1997).
Whole-mount in situ hybridisation
For dystroglycan, a 492 bp product was amplified from cDNA, using 5'-AGAGCTGTAGAAGGGCGAGA-3' forward and 5'-AGTGCATAGACGCCTCCAAC-3' reverse primers, cloned and used as a template to generate a digoxygenin riboprobe. This region is approximately half 5'UTR and half ORF. For dystrophin, primers were designed to the published sequence (5'-GGATCTCCAGGCAGAGATTG-3' forward and 5'-GGAGCTCCATCAGCCTCTC-3' reverse), to amplify a 599 bp cDNA fragment (Bolanos-Jimenez et al., 2001). The PCR product was cloned and used as a template.
Whole mount in situ hybridisation was carried out according to published protocols (Thisse et al., 1993).
Antisense morpholino oligonucleotide injections
Using the 5' sequence around the putative start of translation we designed an anti-sense morpholino oligonucleotide (MO, Gene Tools) to interfere with dystroglycan translation. The sequence used was 5'-CATGCCTGCTTTTATTTTCCCTCGC-3'. A volume of 1.4 nl was injected through the chorion of single cell embryos to deliver 7 ng of MO. For control MO we used the Gene Tools standard control 5'-CCTCTTACCTCAGTTACAATTTATA-3'.
Immunohistochemistry
Protocols were standard with the following modifications:
Rabbit anti-laminin (Sigma L-9393, 1:400); embryos were fixed in 4% paraformaldehyde overnight at 4°C and then 100% methanol, followed by washes in phosphate-buffered saline, 0.1% Tween 20 (PBT) and digestion in 10 µg/ml proteinase K (10 minutes). Mouse anti-ß-dystroglycan (Novocastra, 1:50); embryos were fixed for 2 hours at room temperature in 4% paraformaldehyde, then placed in 100% methanol. Anti-dystrophin (Sigma MANDRA-1, 1:100) or monoclonal F59 anti-slow-twitch myosin (Devoto et al., 1996; Evans et al., 1988
); embryos were placed straight into 100% methanol. Anti-acetyl-
-tubulin (Sigma T 6793, 1:1000); embryos were fixed in 2% TCA for 3 hours at room temperature, followed by washes in PBT and digestion in 0.025% trypsin in PBT (4 minutes on ice).
Electron microscopy
Whole zebrafish embryos were dechorionated manually and fixed overnight with 2% glutaraldehyde, 2% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.2 (SCB). They were washed for 10 minutes in SCB and post-fixed for 1 hour in 1% osmium tetroxide, SCB. They were washed again with SCB and stained en bloc with 1% aqueous uranyl acetate for 1 hour. The samples were then dehydrated through a graded ethanol series, followed by two changes of propylene oxide over 20 minutes and embedded in Epon resin (Agar Scientific). Ultra thin sections (50 nm) were cut and mounted on pioloform coated slot grids and stained with 1% aqueous uranyl acetate for 15 minutes followed by Reynolds lead citrate for 7 minutes. Sections were visualised in a Jeol 1200 EX electron microscope.
Detection of AChR clusters
Embryos were incubated in 5 µM tetramethylrhodamine--bungarotoxin (Molecular probes) in L15 medium (Life Technologies), 15% DMSO for 30 minutes at 4°C, then washed five times in L15 and viewed under fluorescence.
Accession Number
The full-length zebrafish dystroglycan cDNA sequence has been submitted to GenBank and the Accession Number is AF483476.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Zebrafish dystroglycan is maternally expressed. Using whole-mount in situ hybridisation, we detected mRNA expression at the 128-cell stage, before the onset of zygotic transcription (Fig. 1A). The transcript is ubiquitously expressed throughout gastrulation, but by the tailbud stage expression is restricted to the midline and head (Fig. 1D,E). At the beginning of somitogenesis, we detected dystroglycan mRNA in adaxial cells and in the developing CNS. At this stage, midline expression is reduced (Fig. 1F). By the 12-somite stage, we detected expression throughout the paraxial mesoderm and developing CNS (Fig. 1H). Transverse sections reveal that dystroglycan mRNA is present in the immature notochord and adaxial cells in the tail (Fig. 1I, upper section) but not at the level of the hindbrain (Fig. 1I, lower section). CNS expression is seen at both axial levels. At 24 hours post-fertilisation (hpf) we observed expression in the CNS and mesoderm. Although there is little to no expression in the notochord, cells of the hypochord express dystroglycan at high levels (Fig. 1J).
|
|
We focused our attention on the skeletal muscle development of dystroglycan morphants, as this is a tissue known to be affected in mouse dystroglycan mutants (Cote et al., 1999). The F59 antibody recognises a myosin isoform expressed by slow-twitch muscle fibres (Devoto et al., 1996
; Evans et al., 1988
). In embryos that lack dystroglycan, the overall morphology of the slow-twitch muscle is normal (Fig. 3A,B). Closer inspection reveals, however, that muscle fibres in morphants are less fasciculated than in control MO-injected embryos. This indicates that removal of dystroglycan has no effect on slow-twitch muscle differentiation per se but does affect organisation of the muscle tissue.
|
To investigate the effect of removing dystroglycan on muscle integrity, we sectioned developing somites of 28 hpf and 48 hpf control MO- and dystroglycan MO-injected embryos (Fig. 4). Light micrographs of transverse sections revealed that the cellular appearance of muscle in dystroglycan morphants was less organised than in control embryos. We observed numerous lesions within the somitic tissue (Fig. 4B). In the ventral region of morphant embryos, we found darkly stained cells possessing the morphology of apoptotic cells. Electron micrographs reveal that the lesions we observed are swollen cells with intact nuclear membranes and normal mitochondria, which are characteristics of necrotic cells (Fig. 4D). Hence, in dystroglycan morphants we found cells dying via each of the two known mechanisms: apoptosis and necrosis. In muscle tissue, however, we found cells dying only via necrosis. Electron microscopy also revealed damage to the subcellular organisation of dystroglycan-deficient muscle cells. Cross-sections through morphant muscle cells showed a clear presence of actin-myosin filament bundles (Fig. 4F); however, longitudinal sections revealed a huge reduction in the number of sarcomeres (Fig. 4I) and the sarcomeres that could be discerned were clearly aberrant (Fig. 4H). Finally, the abundant sarcoplasmic reticulum clearly visible in both longitudinal and cross-sections of control muscle is virtually absent in dystroglycan morphants.
|
|
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
It is well known that mutations in the Duchenne muscular dystrophy (DMD) gene, which encodes dystrophin, lead to muscular dystrophies and ultimately premature death in humans (Koenig et al., 1987). The Mdx mouse is null for dystrophin but displays a milder form of muscular dystrophy, displaying the muscle pathology typical of the human disease only in the diaphragm (Stedman et al., 1991
). Removing both dystrophin and the closely related utrophin provides a better mouse model for Duchenne muscular dystrophy (Deconinck et al., 1997
; Grady et al., 1997
). By removing dystroglycan, we have disrupted the complex that links both dystrophin and utrophin to the extracellular space. We have shown that removing dystroglycan leads to loss or mislocalisation of dystrophin in skeletal muscles concurrent with a general disruption of muscle integrity, loss of sarcomere organisation and necrosis of the developing muscle. These phenotypes are very similar to those observed in muscle degeneration that occurs in humans suffering from muscular dystrophy or the mouse models of the disease. For example, disruption of the interaction of
dystroglycan and laminin in a mouse cell culture system has been shown to disrupt sarcomere organisation (Brown et al., 1999
).
Although the dystroglycan gene itself has not been identified as a cause of human muscular dystrophy (because mutations probably lead to embryonic lethality) there are several human muscular dystrophy genes known to affect dystroglycan function. For example, Limb-girdle muscular dystrophy 1C (LGMD-1C) is caused by mutations in caveolin 3 (CAV3), which is believed to be important for the normal organisation of T-tubules and correct membrane localisation of dystroglycan (Galbiati et al., 2001; Minetti et al., 1998
). When caveolin 3 is overexpressed in muscle of transgenic mice, it leads to downregulation of ß dystroglycan expression and a Duchenne-like muscular dystrophy (Galbiati et al., 2000
). Altering the glycosylation state of
dystroglycan has also been found to cause muscular dystrophy. For example, Muscle-eye-brain disease (MEB) is caused by mutations in a glycosyltransferase, POMGnT1, which is likely to mediate the O-mannosyl glycosylation of
dystroglycan (Kano et al., 2002
; Yoshida et al., 2001
). Similarly, markedly reduced glycosylation of
dystroglycan is thought to be responsible for the phenotype of myodystophic (Myd) mice, which carry a deficiency in the gene encoding a glycosyltranferase-like protein called large (Grewal et al., 2001
). Thus, in mammals there is a correlation between compromised dystroglycan function and muscular dystrophy.
Comparing the phenotype of zebrafish dystroglycan morphants with standard mammalian models of muscular dystrophy, such as Mdx mutant mice, a key difference is the timing of the dystrophic phenotype. There are several possible explanations for this. The early onset of muscle pathology seen in zebrafish dystroglycan morphants may relate to a developmental role of dystroglycan, perhaps in basement membrane organisation. There may be a similar early requirement for dystroglycan in mouse muscle development, but this has not been addressed because of the peri-implantation lethality (Williamson et al., 1997). Alternatively, in human muscular dystrophy and in the mouse models of the disease, the comparatively late onset of the disease may be the result of regeneration that does not occur in zebrafish. It is known that overexpression of a muscle-specific isoform of the insulin-like growth factor, IGF1, can sustain hypertrophy of muscle and prevent muscle loss because of age-related muscle atrophy (Musaro et al., 2001
). Indeed, IGF1 is found to be upregulated in Mdx mutant muscle (De Luca et al., 1999
). Hence, the reduced severity of the mouse Mdx mutant compared with human Duchenne or Becker muscular dystrophy may be due, in part, to enhanced regenerative capacity of mouse muscle. Zebrafish embryonic muscle may not possess the regenerative capacity of mouse or human muscle. While we cannot examine the role of regeneration in dystroglycan morphants, because of the transient nature of the morpholino-based approach, the knowledge of the morphant phenotype will now guide us to identify dystroglycan mutants as well as other muscular dystrophy mutants that were probably observed in chemical mutagenesis screens (Driever et al., 1996
; Haffter et al., 1996
).
What remains clear is that there is a sharp contrast between the mouse and zebrafish in the onset of a requirement for dystroglycan. In the zebrafish there is no equivalent need to form a BM such as the mammalian Reicherts membrane until organogenesis is under way. This is also apparent in laminin mutants, which appear morphologically normal prior to displaying a notochord differentiation defect (Parsons et al., 2002). Zebrafish are therefore a useful model to study the role of dystroglycan and other ECM components during late embryogenesis. Dystroglycan is maternally expressed and later becomes restricted to the midline prior to somitogenesis, when the first requirement for a BM and laminin 1 occurs in zebrafish. Although dystroglycan is a laminin receptor, removing dystroglycan has no effect on notochord differentiation. Dystroglycan morphant embryos do not resemble zebrafish laminin mutants (sly, gup) at 24 hpf (Parsons et al., 2002
). Hence, dystroglycan is not required for laminin 1 accumulation or BM formation in zebrafish embryos. Moreover, we find that laminin 1 is not required for correct dystroglycan localisation. It is possible that there is functional redundancy between dystroglycan and other laminin receptors expressed in the midline such as the integrins (Whittaker and DeSimone, 1993
).
Dystroglycan can bind other components of the ECM and the role of laminin may be redundant to other proteins containing laminin G-like modules such as agrin or perlecan (Winder, 2001). Congenital muscular dystrophy in humans and mice has been linked to mutations in laminin chain
2 (Campbell, 1995
). The antibody we used in this study recognises the heterotrimer laminin 1 (
1 ß1
1). It is possible that another laminin heterotrimer consisting of completely different chains from those found in laminin 1 may be important in the biology of dystroglycan.
Dystroglycan has been implicated in the establishment of AChR clusters at the NMJ. Work in tissue culture suggests that removing dystroglycan abrogates AChR clustering (Jacobson et al., 1998). However, other studies using dystroglycan mutant myotubes in culture have shown AChR clusters do form in the absence of dystroglycan (Grady et al., 2000
). In the zebrafish, we found that dystroglycan removal has no effect on the localisation or appearance of AChR clusters. Indeed, we do not observe dystroglycan in the synaptic region of muscle cells, but rather at the transverse myoseptum. From these data, we conclude that dystroglycan is unlikely to have a role in the establishment of AChR clusters in the embryonic zebrafish. Nevertheless the dystrophin-glycoprotein complex may be required for the maintenance of AChR clustering as has been suggested (Grady et al., 2000
). It has also been suggested that dystroglycan is important for cell adhesion in the CNS through its association with neurexins (Sugita et al., 2001
). In zebrafish dystroglycan morphants, however, the gross morphology and axonal scaffold of the brain is unaffected.
There are several features of zebrafish embryogenesis and genetics that make it well suited for the study of muscular dystrophy. Zebrafish embryonic skeletal muscle is simply organised, with single myotubes extending across each somite and attached at either end to the ECM of the transverse myoseptum. Loss of dystroglycan and the DGC leads to a less pleiotrophic phenotype than in mouse. Finally, generation of zebrafish embryos that lack dystroglycan is convenient and inexpensive. These embryos should facilitate the study of the cellular pathogenesis associated with muscular dystrophy and can be used to examine interactions of dystroglycan with other gene products that have known or suspected roles in muscular dystrophy aetiology. In addition, dystroglycan morphant or mutant zebrafish could be used to screen for agents capable of suppressing the dystrophic phenotype. Finally, several human muscular dystrophies, such as facioscapulohumeral muscular dystrophy (FSHD), have been mapped but the underlying disease gene remains unknown (van Geel et al., 2002). Zebrafish homologues of candidate human genes from a critical region can be readily identified using the zebrafish genome and EST sequence. The fact that we can now recognise muscular dystrophy in zebrafish combined with the efficacy of antisense morpholino oligonucleotides make zebrafish a fast and effective means with which to identify the specific genetic causes of a variety of muscular dystrophies.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Bolanos-Jimenez, F., Bordais, A., Behra, M., Strahle, U., Sahel, J. and Rendon, A. (2001). dystrophin and Dp71, two products of the DMD gene, show a different pattern of expression during embryonic development in zebrafish. Mech. Dev. 102, 239-241.[Medline]
Brown, S. C., Fassati, A., Popplewell, L., Page, A. M., Henry, M. D., Campbell, K. P. and Dickson, G. (1999). Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycan-laminin interaction. J. Cell Sci. 112, 209-216.
Campbell, K. P. (1995). Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 80, 675-679.[Medline]
Chamberlain, J. (1999). The dynamics of dystroglycan. Nat. Genet. 23, 256-258.[Medline]
Cohen, M. W., Jacobson, C., Yurchenco, P. D., Morris, G. E. and Carbonetto, S. (1997). Laminin-induced clustering of dystroglycan on embryonic muscle cells: comparison with agrin-induced clustering. J. Cell Biol. 136, 1047-1058.
Colognato, H. and Yurchenco, P. D. (2000). Form and function: the laminin family of heterotrimers. Dev. Dyn. 218, 213-234.[Medline]
Cote, P. D., Moukhles, H., Lindenbaum, M. and Carbonetto, S. (1999). Chimaeric mice deficient in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses. Nat. Genet. 23, 338-342.[Medline]
De Luca, A., Pierno, S., Camerino, C., Cocchi, D. and Camerino, D. C. (1999). Higher content of insulin-like growth factor-I in dystrophic mdx mouse: potential role in the spontaneous regeneration through an electrophysiological investigation of muscle function. Neuromuscular Disord. 9, 11-18.[Medline]
Deconinck, A. E., Rafael, J. A., Skinner, J. A., Brown, S. C., Potter, A. C., Metzinger, L., Watt, D. J., Dickson, J. G., Tinsley, J. M. and Davies, K. E. (1997). Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90, 717-727.[Medline]
Devoto, S. H., Melancon, E., Eisen, J. S. and Westerfield, M. (1996). Identification of separate slow and fast muscle precursor cells in vivo, prior to somite formation. Development 122, 3371-3380.
Driever, W., Solnica-Krezel, L., Schier, A. F., Neuhauss, S. C., Malicki, J., Stemple, D. L., Stainier, D. Y., Zwartkruis, F., Abdelilah, S., Rangini, Z. et al. (1996). A genetic screen for mutations affecting embryogenesis in zebrafish. Development 123, 37-46.
Evans, D., Miller, J. B. and Stockdale, F. E. (1988). Developmental patterns of expression and coexpression of myosin heavy chains in atria and ventricles of the avian heart. Dev. Biol. 127, 376-383.[Medline]
Galbiati, F., Volonte, D., Chu, J. B., Li, M., Fine, S. W., Fu, M., Bermudez, J., Pedemonte, M., Weidenheim, K. M., Pestell, R. G. et al. (2000). Transgenic overexpression of caveolin-3 in skeletal muscle fibers induces a Duchenne-like muscular dystrophy phenotype. Proc. Natl. Acad. Sci. USA 97, 9689-9694.
Galbiati, F., Engelman, J. A., Volonte, D., Zhang, X. L., Minetti, C., Li, M., Hou, H., Jr, Kneitz, B., Edelmann, W. and Lisanti, M. P. (2001). Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t- tubule abnormalities. J. Biol. Chem. 276, 21425-21433.
Grady, R. M., Teng, H., Nichol, M. C., Cunningham, J. C., Wilkinson, R. S. and Sanes, J. R. (1997). Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90, 729-738.[Medline]
Grady, R. M., Zhou, H., Cunningham, J. M., Henry, M. D., Campbell, K. P. and Sanes, J. R. (2000). Maturation and maintenance of the neuromuscular synapse: genetic evidence for roles of the dystrophin-glycoprotein complex. Neuron 25, 279-293.[Medline]
Grewal, P. K., Holzfeind, P. J., Bittner, R. E. and Hewitt, J. E. (2001). Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. Nat. Genet. 28, 151-154.[Medline]
Haffter, P., Granato, M., Brand, M., Mullins, M. C., Hammerschmidt, M., Kane, D. A., Odenthal, J., van Eeden, F. J., Jiang, Y. J., Heisenberg, C. P. et al. (1996). The identification of genes with unique and essential functions in the development of the zebrafish, Danio rerio. Development 123, 1-36.
Holt, K. H., Crosbie, R. H., Venzke, D. P. and Campbell, K. P. (2000). Biosynthesis of dystroglycan: processing of a precursor propeptide. FEBS Lett. 468, 79-83.[Medline]
Hukriede, N. A., Joly, L., Tsang, M., Miles, J., Tellis, P., Epstein, J. A., Barbazuk, W. B., Li, F. N., Paw, B., Postlethwait, J. H. et al. (1999). Radiation hybrid mapping of the zebrafish genome. Proc. Natl. Acad. Sci. USA 96, 9745-9750.
Jacobson, C., Montanaro, F., Lindenbaum, M., Carbonetto, S. and Ferns, M. (1998). alpha-Dystroglycan functions in acetylcholine receptor aggregation but is not a coreceptor for agrin-MuSK signaling. J. Neurosci. 18, 6340-6348.
Kano, H., Kobayashi, K., Herrmann, R., Tachikawa, M., Manya, H., Nishino, I., Nonaka, I., Straub, V., Talim, B., Voit, T. et al. (2002). Deficiency of alpha-Dystroglycan in Muscle-Eye-Brain Disease. Biochem. Biophys. Res. Commun. 291, 1283-1286.[Medline]
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C. and Kunkel, L. M. (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509-517.[Medline]
Li, X., Chen, Y., Scheele, S., Arman, E., Haffner-Krausz, R., Ekblom, P. and Lonai, P. (2001). Fibroblast growth factor signaling and basement membrane assembly are connected during epithelial morphogenesis of the embryoid body. J. Cell Biol. 153, 811-822.
Lohikangas, L., Gullberg, D. and Johansson, S. (2001). Assembly of laminin polymers is dependent on beta1-integrins. Exp. Cell Res. 265, 135-144.[Medline]
Minetti, C., Sotgia, F., Bruno, C., Scartezzini, P., Broda, P., Bado, M., Masetti, E., Mazzocco, M., Egeo, A., Donati, M. A. et al. (1998). Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat. Genet. 18, 365-368.[Medline]
Musaro, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E. R., Sweeney, H. L. and Rosenthal, N. (2001). Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 27, 195-200.[Medline]
Nasevicius, A. and Ekker, S. C. (2000). Effective targeted gene knockdown in zebrafish. Nat. Genet. 26, 216-220.[Medline]
Nielsen, H., Engelbrecht, J., Brunak, S. and von Heijne, G. (1997). Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Protein Eng. 10, 1-6.[Abstract]
Parsons, M. J., Pollard, S. M., Saude, L., Feldman, B., Coutinho, P., Hirst, E. M. A. and Stemple, D. L. (2002). Zebrafish mutants indentify an essential role for laminins in notochord formation. Development 129, 3137-3146.
Smyth, N., Vatansever, H. S., Murray, P., Meyer, M., Frie, C., Paulsson, M. and Edgar, D. (1999). Absence of basement membranes after targeting the LAMC1 gene results in embryonic lethality due to failure of endoderm differentiation. J. Cell Biol. 144, 151-160.
Stedman, H. H., Sweeney, H. L., Shrager, J. B., Maguire, H. C., Panettieri, R. A., Petrof, B., Narusawa, M., Leferovich, J. M., Sladky, J. T. and Kelly, A. M. (1991). The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352, 536-539.[Medline]
Sugita, S., Saito, F., Tang, J., Satz, J., Campbell, K. and Sudhof, T. C. (2001). A stoichiometric complex of neurexins and dystroglycan in brain. J. Cell Biol. 154, 435-445.
Thisse, C., Thisse, B., Schilling, T. F. and Postlethwait, J. H. (1993). Structure of the zebrafish snail1 gene and its expression in wild-type, spadetail and no tail mutant embryos. Development 119, 1203-1215.
van Geel, M., Dickson, M. C., Beck, A. F., Bolland, D. J., Frants, R. R., van der Maarel, S. M., de Jong, P. J. and Hewitt, J. E. (2002). Genomic analysis of human chromosome 10q and 4q telomeres suggests a common origin. Genomics 79, 210-217.[Medline]
Whittaker, C. A. and DeSimone, D. W. (1993). Integrin alpha subunit mRNAs are differentially expressed in early Xenopus embryos. Development 117, 1239-1249.
Williamson, R. A., Henry, M. D., Daniels, K. J., Hrstka, R. F., Lee, J. C., Sunada, Y., Ibraghimov-Beskrovnaya, O. and Campbell, K. P. (1997). Dystroglycan is essential for early embryonic development: disruption of Reicherts membrane in Dag1-null mice. Hum. Mol. Genet. 6, 831-841.
Winder, S. J. (2001). The complexities of dystroglycan. Trends Biochem. Sci. 26, 118-124.[Medline]
Yoshida, A., Kobayashi, K., Manya, H., Taniguchi, K., Kano, H., Mizuno, M., Inazu, T., Mitsuhashi, H., Takahashi, S., Takeuchi, M. et al. (2001). Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 1, 717-724.[Medline]